We are a biotechnology company developing our proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for respiratory diseases. Surfactants are substances that are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen and to maintain proper airflow through the respiratory system. The absence or depletion of surfactants is involved in a number of respiratory diseases.

Our  technology produces a precision-engineered surfactant that is designed to mimic the essential properties of natural human lung surfactant.  We believe that through our technology, pulmonary surfactants have the potential, for the first time, to address respiratory diseases where there are few or no approved therapies available.

Our SRT pipeline is initially focused on the most significant respiratory conditions prevalent in the Neonatal Intensive Care Unit (NICU).  Our lead product, SurfaxinÒ (lucinactant), for the prevention of Respiratory Distress Syndrome (RDS) in premature infants, has received an Approvable Letter from the U.S. Food and Drug Administration (FDA).  Surfaxin is also being developed for the treatment of Bronchopulmonary Dysplasia (BPD, also known as Chronic Lung Disease) in premature infants.  In addition, we are developing Aerosurf™, aerosolized SRT administered through nasal continuous positive airway pressure (nCPAP), to address neonatal respiratory failures.

Our SRT technology is also being developed to address the various respiratory conditions affecting pediatric, young adult and adult patients in the critical care and other hospital settings.  We have completed a Phase 2 clinical trial to address Acute Respiratory Distress Syndrome (ARDS) in adults, and are developing aerosol formulations of SRT to address Acute Lung Injury (ALI), cystic fibrosis, and other respiratory conditions.

We are implementing a business strategy that includes: (i) undertaking actions intended to gain regulatory approvals for Surfaxin for RDS in premature infants; (ii) investing in development of SRT pipeline programs, including Aerosurf; (iii) continued investment in manufacturing capabilities at the manufacturing operations in New Jersey and, potentially, additional facilities to be built or acquired by us for the production of surfactant drug products; and (iv) potentially entering into strategic partnerships for the development and commercialization of our SRT product candidates.